Urokinase-type plasminogen activator receptor: A beacon of malignancy?

Clinical Cancer Research

Volumn 14, Issue 18, 2008, Pages 5643-5645

  Drapkin, Ronny ^a,b,c   Clauss, Adam ^a,c   Skates, Steven ^c,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; UROKINASE RECEPTOR; CA125 PROTEIN, RAT; CELL SURFACE RECEPTOR; PROTEIN; TUMOR MARKER; UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTORS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTORS;

CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; HUMAN; OVARY CANCER; PATIENT CARE; PATIENT REFERRAL; PRIORITY JOURNAL; PROTEIN BINDING; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; TREATMENT RESPONSE; BLOOD; FEMALE; MORTALITY; NOTE; OVARY TUMOR; PATHOLOGY; PROGNOSIS;

FEMALE; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS; PROTEINS; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL;

EID: 53249136459     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1557     Document Type: Short Survey

References (14)

1. Henic E, Borgfeldt C, Christensen lJ, Casslén B, and Høyer-Hansen G. Cleaved forms of the uPA receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res 2008;14:5785-93.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2008. CA Cancer J Clin 2008;58:71-96.
3. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
4. Bast RC, Jr., KlugTL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309:883-7.
5. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004;3:355-66.
6. Gohagan JK, Prorok PC, Hayes RB, Kramer BS; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 2000;21:251-72S.
7. Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet1999;353:1207-10.
8. de Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 2003; 24:13-39.
9. Hildenbrand R, Gandhari M, Stroebel P, Marx A, Allgayer H, Arens N. The urokinase-system-role of cell proliferation and apoptosis. Histol Histopathol 2008;23:227-36.
10. PillayV, Dass CR, Choong PFM. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 2007;25:33-9.
11. Ransohoff D. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol 2007;60:1205-19.
12. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402-8.
13. Aletti GD, Dowdt SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006;107:77-85.
14. Chan JK, Kapp DS, Shin JY, et al. Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet Gynecol 2007;109:1342-50.